Evidence map›Paper›PMID 35034345›Full record

Trial reportClinical drug investigation2022

Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers.

Milko Radicioni, Carol Caverzasio, Stefano Rovati, Andrea Maria Giori, Irma Cupone, Fabio Marra, Giuseppe Mautone

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical drug investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Vitamin DFrontiers in immunology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. A comparative absorption study of sucrosomialFrontiers in nutrition · 2023
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Milko RadicioniCross Research S.A, Phase I Unit, F.A Giorgioli n 14, 6864, Arzo, Switzerland. milko.radicioni@croalliance.com.ORCID http://orcid.org/0000-0002-3940-8375
Carol CaverzasioIBSA Institut Biochimique SA, 6915, Pambio-Noranco, Switzerland.
Stefano RovatiIBSA Institut Biochimique SA, 6915, Pambio-Noranco, Switzerland.
Andrea Maria GioriIBSA Farmaceutici Italia Srl, 26900, Lodi, Italy.
Irma CuponeIBSA Farmaceutici Italia Srl, 26900, Lodi, Italy.
Fabio MarraIBSA Farmaceutici Italia Srl, 26900, Lodi, Italy.
Giuseppe MautoneIBSA Institut Biochimique SA, 6915, Pambio-Noranco, Switzerland.
IBSA Farmaceutici (Italy) · ITIBSA Institut Biochimique (Switzerland) · CHRadiall (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAn orally disintegrating film (ODF) formulation of vitamin D3 that dissolves rapidly in the mouth without drinking or chewing may be a worthwhile alternative to currently available drug products for therapeutic vitamin D supplementation. This study aimed to compare the bioavailability of a single dose of a vitamin D3 25000 I.U. ODF with those of a marketed oral vitamin D3 preparation in healthy subjects.

methodsThis Phase 1, randomised, parallel-group, open-label study compared the pharmacokinetics of calcifediol [25(OH)D3], the precursor of bioactive vitamin D3, after a single dose of a new vitamin D3 25,000 I.U. ODF with those of a Reference formulation (vitamin D3 25000 I.U./2.5 mL oral solution) in healthy adult subjects using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. The primary objective was bioavailability under fed conditions, defined as maximum plasma concentration (C

resultsForty-eight healthy subjects were randomised and completed the study. Overall, the pharmacokinetic profile was very similar across the three treatment groups, and bioavailability did not significantly differ among treatments. Under fed conditions, mean 25(OH)D3 plasma values for C

conclusionThe new ODF 25000 I.U. formulation provided a valuable alternative to the marketed oral solution for therapeutic vitamin D supplementation, with a bioavailability that was slightly higher than that of the vitamin D3 oral solution administered under the same conditions.

trial registrationThe study was retrospectively registered with the ISRCTN Registry (Registry code: ISRCTN13208948) on 27 November 2020.

Indexed as

CholecalciferolTandem Mass SpectrometryAdministration, OralAdultArea Under CurveBiological AvailabilityChromatography, LiquidCross-Over StudiesFastingHealthy VolunteersHumansTabletsTherapeutic EquivalencyCholecalciferolTablets

Identifiers

PMID35034345
PMCPMC8761109
OpenAlexW4205108637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.